3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Interventions
Rituximab
17
Cyclophosphamide
8
zanubrutinib
7
Bendamustine Hydrochloride
7
obinutuzumab
6
Lenalidomide
6
venetoclax
5
blinatumomab
5
acalabrutinib
5
Vincristine
5
fludarabine
4
Prednisone
4
Methotrexate
4
Doxorubicin
4
Cytarabine
4
Brentuximab Vedotin
4
ibrutinib
3
Specimen Handling
3
Dexamethasone
3
Crizotinib
3
tisagenlecleucel
2
tafasitamab
2
polatuzumab vedotin
2
pirtobrutinib
2
pegaspargase
2
idelalisib
2
duvelisib
2
axicabtagene ciloleucel
2
avapritinib
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Cobicistat
×
Lymphoid
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA